CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187

Available online at: http://www.iajps.com Research Article

IMPLEMENTATION OF DATA INTEGRITY PRINCIPLES IN PHARMACEUTICAL QUALITY ASSURANCE

Sayed Shaffath Ali, Neeradi Anusha, Dr. Shaik shabeer, Dr. P.Poli Reddy
Department of Pharmaceutics, Nalanda College Of Pharmacy, Charlapally, Nalgonda-508001, Telangana

Abstract:
In the pharmaceutical world, the maintaining of data integrity represents one of the most critical aspects of ensuring that medications reach patients safely and effectively. This concept goes far beyond simple record keeping it encompasses the entire journey of information from initial research through final product delivery, ensuring that every piece of data remains accurate, reliable, complete, and consistent throughout this process. The regulatory landscape has evolved significantly, with organizations like the FDA establishing comprehensive guidelines such as 21 CFR Part 11, alongside internationally recognized frameworks like ALCOA+ and ICH Q7. These standards emphasize that pharmaceutical data must be attributable, legible, contemporaneous, original, and accurate, while also being complete, consistent, enduring, and available whenever needed. The importance of data integrity extends well beyond regulatory compliance. When pharmaceutical companies maintain robust data practices, they build trust with patients, protect public health, and foster transparency across all operational levels. However, the path to achieving this ideal is fraught with challenges, including human errors, inadequate digital infrastructure, poor documentation practices, and increasingly sophisticated cybersecurity threats. To address these challenges, companies are implementing comprehensive risk-based approaches, investing in advanced digital technologies, and cultivating organizational cultures that prioritize quality and accountability. This paper explores the fundamental principles governing data integrity, examines regulatory requirements, identifies common pitfalls, and presents best practices for maintaining data integrity in pharmaceutical operations. Modern technologies like automation, artificial intelligence, and block chain further strengthen data security and traceability.

Corresponding author:
Sayed Shaffath Ali,
Assistant professor Department of Pharmaceutics
Nalanda College Of Pharmacy
Charlapally, Nalgonda- 508001, Telangana

QR CODE

Please cite this article in press Sayed Shaffath Ali et al., Implementation Of Data Integrity Principles In Pharmaceutical Quality Assurance, Indo Am. J. P. Sci, 2026; 13(07).

INTRODUCTION:

1.1 Back ground Of The Study

Theobjectiveofthisarticleistoexaminethechallenges andbeststrategies for incorporating data integrity in the pharmaceutical industry to ensure regulatory compliance. It highlights the importance of data governance policies, secure data handling processes, and the use of the ALCOA framework for implementing Good Documentation Practices. In pharmaceutical Quality Assurance (QA),dataintegrity play sacritical role in ensuring that all records related to manufacturing, quality control, validation, calibration, and documentation are trustworthy and traceable. Poor data management practice scanlead to data manipulation, inaccurate results, regulatory non-compliance, product recalls, and risks to patient health.(1)

1.2 PHARMACEUTICALQUALITYASSURANCE OVERVIEW

Pharmaceutical quality assurance in data integrity implementation is the set of controls, processes, and behaviors that ensure GxP data is complete, accurate, trustworthy, and available throughout its lifecycle. In practice, QA owns the governance framework that makes data integrity part of routine quality management, not just a compliance check.

Core QA role

Quality assurance acts asthe independent oversight function that defines expectations, monitors adherence, and verifies that data-handling practices support product quality and patient safety. It typically covers documentation conData integrity is the accuracy, completeness, consistency, and reliability of data throughout its entire life cycle. It ensures that data is recorded, maintained, and reported correctly without any unauthorized alteration or loss.trol, review of audit trails, deviation management, change control, and periodic effectiveness checks.

Main implementation pillars

Governance & accountability. QA sets policies, assigns ownership, and makes sure responsibilities are clear across operations, QC, manufacturing, and IT.

ALCOA/ALCOA+principles. Data should be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available.

Risk-based oversight. QA prioritizes higher-risk processes such as critical manufacturing records, laboratory data, and release decisions.

- **System controls.** Electronic records, audit trails, role-based access, and secure signatures help prevent unauthorized changes and improve traceability.
- **Training and culture.** Staff training, open reporting, and a quality-first culture are essential because many integrity failures come from human behavior and weak oversight.

Typical QA activities

QA usually implements data integrity through practical routines such as review ingraw data against final reports, checking audit trails for unusual activity, validating computerized systems, and ensuring records are retained correctly. It also investigates discrepancies, trends recurring issues, and confirms that CAPAactions actually reduce future risk.

Regulatory focus

Common expectations come from FDA 21 CFR Part 11, FDA cGMP requirements, EU GMP Annex 11, and broader guidance from EMA, WHO, PIC/S, and MHRA-aligned approaches. These frameworks all emphasize reliable records, controlled systems, and data that remains trustworthy across its lifecycle.

Simple implementation model

A practical QA rollout often follows this sequence:

1. Assess current data risks in paper & electronic systems.
2. Define the data integrity policies and record ownership.
3. Validatescriticalsystemsandclosesthecontrolgaps. Trainusersongooddocumentationandescalationrules .
4. Monitor through audits, trendreviews, CAPA follow-up.

Common failure points

Frequent weaknesses include backdating, incomplete raw data, shared passwords, poor audit trail review, weak metadata control, and informal workarounds outside validated systems. QA reduces these risks by combining procedural controls with technical safeguards and routine oversight.(2)

PRINCIPLESOFDATAINTEGRITY



Fig: Data Integrity Principles

Need for Data Integrity

The pharmaceutical industry operates under a fundamental premise : every product that reaches a patient must be supported by comprehensive evidence demonstrating its safety and effectiveness. This requirement creates multiple layers of necessity for maintaining data integrity across all operations.

Beyond patient safety, data integrity also ensures accurate evaluation of how well a product works, helps prevent adverse drug reactions through complete and reliable records, and supports research and development by providing trustworthy data for future improvements.

Regulatory compliance is also a key part of data integrity. Since pharmaceutical regulations differ across countries, maintaining accurate and reliable data helps companies meet these requirements and ensures smoother inspections and submissions.

Objectives of the study

METHODOGY

There are some main objectives of data management and data integrity in pharmaceutical industry. Let's check it out:

- Facilitate the sharing of data within the organization and with externalpartners.
- Enableeffectivemonitoringofproductsafetyandefficacythroughaccurate tracking of adverse events, clinical trial results, etc.
- Support supply chain management by providing accurate inventory and production data.
- Facilitate effective resource allocation byproviding accurate information on resource utilization.
- Enable effective risk management by identifying potential risks through analysis of relevant data.



Figure 1 Data Integrity Lifecycle Management

Fig3: Pharmaceutical Data Integrity

Data Governance–Establishes policies, procedures. es, and responsibilities for managing data.
Policies and Procedures

Data Management–Focuses on proper collection, recording, storage ,and maintenance of data. Data Documentation
Data Quality –Ensures data isaccurate, complete, and fit for its intended use. Data Validation
DataSecurity–
Protectsdatafromunauthorizedaccess, modification,orloss. Access Control Risk Management Strategies

Effective risk management requires a comprehensive approach that addresses technical, procedural, and cultural aspects of data integrity throughout the entire lifecycle of computerized systems.

1.1 Risk Assessment

Data Integrity Risk Assessment (DIRA) identifies processes that generate data, reviews data formats and controls, and documents risks and criticality. It helps organizations understand vulnerabilities and develop strategies to protect data accuracyand reliability using a research-based, analytical approach. The DIRA must be documented and regularly updated. It evaluates risks in GxP systems, personnel, training, and outsourced work. Risks should be controlled and communicated, with reviews performed throughout the data lifecycle based on risk level.

1.2 Mitigation Strategies

Data processing methods must be approve, version compliance with regulatory requirements and a controlled & protected from unauthorizes changes. Commitment to continuous improvement are essential. Even validated systems can be risky if users can choose components of a successful data integrity program. Archival means protecting records from alteration or deletion & securely storing them under responsible data management staff for the required retention period.
Data governance. Awareness of the need for strong data governance is growing. Life science companies are now investing in structured governance frameworks with clear policies, procedures, and controls to maintain data integrity.
Technical Management involves ensuring computerized systems compliance with clear requirements for data integrity from a design, validation and maintenance perspective.
Data Storage strategies involve ***s***toring data in multiple locations helps detect discrepancies by providing redundant copies that can be cross-checked.

Data Encryption protects information during data transfer and prevent unauthorized access, organizations should use encryption protocols.

2. Technological Solutions

Computersystemsneedstrongcontrolstopreventunauthorizedaccessor data changes. All edits must be logged, and critical actions restricted. Backups must be securely stored to prevent loss or tampering.Cloud storage is popular for its scalability, low cost, and easy access.Archival andhybridstorageoptionsletorganizationsmanagedatamoreefficiently.
WithadvanceslikeSSDsandemergingtechnologies,storagewillbecome faster, larger, and more cost effective.

2.1 Electronic system

Biometric signatures authenticate a user's identity by measuring unique and measurable physical characteristics specific to the individual. AdvancedsystemslikeElectronicBatchRecords(EBRs),LIMS,andPAT have streamlined data recording and real-time process control in pharmaceutical manufacturing. Tools such as NIR and Raman spectroscopy enable continuous, non-destructive monitoring, supporting fasteroptimization,betterqualityassurance,andreal-timeproductrelease.

2.1.1 Laboratory information management systems- LIMS:

A Laboratory Information Management System (LIMS) is software that improves laboratory efficiency by managing workflows, tracking data, handling results, and supporting analysis. It can also integrate with Electronic LaboratoryNotebooks. Its features vary by industryneeds for example, QC labs focus on meeting specification requirements, while R&D labs use LIMS to manage stability and pharmacokinetic data.

2.1.2 Electronic data capture–EDC:

ElectronicDataCapture(EDC)isacomputer-basedsystemusedtocollect clinical trial data electronically. It replaces paper methods, making data collection faster and more efficient, and helps speed up the development ofdrugsandmedicaldevices.EDCisusedacrossalltrial phases,allowing information to be entered directly into secure software via the internet.

2.1.3 Share point document management system:

Share Point, developed by Microsoft in 2001,isaweb based plat form used for document management, intranet portals, search, and workflow automation. Itsstrongintegrationandcontent management features make it increasingly valuable for pharmaceutical companies.

2.1.4 Enterprise Content Management (ECM):

Enterprise Content Management (ECM), defined by AIIM in 2000, is software that helps capture, manage, store, preserve, and deliver documents and content throughout their lifecycle. It includes tools for web content management,search,workflow,anddocument capture, supporting efficient handling of organizationalin formation from creation to archivalor disposal.

2.2 Audit Trials

RegulationslikeEUGMPAnnex11andUS21CFRPart 11requireaudit trail reviews. Clause 9 states that systems must record all GMP-relevant changes or deletions, withwritten justification foranydata modification. Audit trails must be easy to access, easy to understand, and reviewed regularly.Regulators require pharmaceutical companies to maintain strongaudittrailsinelectronic systems.Thesetrailstrackallchangeswith timestamps, ensuring accountability and transparency.

2.3 Data Backup

Maintaining proper data retention and backup practices is an essential aspect ofan effective data governance framework. Regularlyperforming and testing backups ensures data availability and integrity in case of system failures or disasters. Inadequate backup measures and poor recovery practices can lead to permanent data loss and an inability to restore critical information. Data backup and recovery plans should be established to ensure critical data remains accessible during system failures or data loss incidents. Regular backups are essential for data recovery following breaches.

3. Training and cultural considerations

Data integrity relies on strong processes, secure storage, access controls, and proper training. Companies must clearly communicate policies, and all employees technical and non-technical should be trained to understand their role in protecting patient safety.

3.1 Employee Training

Employees should receive training on proper data documentation and retention. They must understand regulatory requirements, best practices, and the risks of poor documentation.SOPs must guide proper documentation and retention, and all GxP staff need regular, role-based data integrity training. The organization should foster a culture of accurate, complete data and ensure systems, personnel, and facilities support strong integrity controls.

3.2 Organizational Culture

Organizational factors are key to maintaining data integrity. Companies must stay updated on regulatory requirements, identify risks, and apply strong data governance practices to ensure reliable data throughout the product lifecycle.Companies must stay updated on DI requirements and uses trong governance practices to ensurere liable dataacrosstheproductlifecycle.Organizationalcultur estronglyaffectsdataintegrity,itcanlead to poor practices. A strong quality culture that values data integrityat all levels is essential for lasting compliance and reduced risk.

4 Audits and Inspections

Audits check compliance with FDA21 CFR Part 11, EUAnnex 11, and PIC/S. They verify system validation, access control, audit trails, documentation accuracy, and proper data review and approval.

4.1 Internal Audits

Regular internal audits check the effectiveness of data governance. Audit trails must record all changes and system events, with review frequency based on the data's risk and impact on quality and patient safety. Pharmaceutical internal quality audits check compliance with SOPs, GMP, and quality standards while promoting continuous improvement. They also assess risk management, validation, training, and document control systems.

4.2 Regulatory Inspections

Regulators set record retention requirements and inspect companies for compliance. Any deficiencies found may lead to corrective actions or penalties.

PIC/S Guidance: PIC/S offers data integrityguidance, and agencies like CDSCO,USFDA,andEMAconductinspections,inclu dingPre-Approval Inspections. These reviews assess processes, facilities, and equipment to ensure medicines are safe, effective, and consistently high quality.

***5.* FutureTrendsand Innovations**

Future trends in pharmaceutical data integrity will be influenced by technologicaladvancements,changingregulatoryreq uirements,andshifts in the pharmaceutical industry landscape.

5.1 Automation and Artificial Intelligence

Low-code automation streamlines compliance, improves data integrity, and boosts efficiency, helping companies meet evolving regulatory requirements.AIuncoverspatternshumansmaymiss,s peedsupanalysis, reduces experiments, and improves process consistency while lowering validation time and costs.AI supports continuous validation by monitoringsystemperformanceinrealtimeandupdati ngvalidationstatus after changes. In cleaning validation, AI uses image recognition and sensor data to detect residual contaminants accurately. Figure3showsitsapplicationsinthepharmaceuticalse ctor.

Artificial Intelligence (AI): AI strengthens data integrity by reducing human error and processing

large data sets with high accuracy. Its advanced algorithms improve the reliability and quality of data analysis.

Automation and Machine Learning: Emerging technologies like artificialintelligence(AI),machinelearning(ML),and blockchainareset to transform data management throughout its lifecycle, from creation to destruction.These technologies help reduce errors because manual data entry is prone to mistakes, while automation greatly minimizes them.

Fig:Use of AI in Pharmaceutical Sector

5.2 Block chain Technology

Blockchain improvesdata integrity and traceability inthe pharmaceutical supply chain by providing secure, transparent, and tamper-proof records of all transactions. Integrating blockchain with Enterprise Resource Planning (ERP) systems marks a significant advancement in the management of supply chains and data integrity. It is a promising technology in the pharmaceutical industry due to its core features of security, authenticity, immutability, and transparency, whichensure end-to-end verification. Blockchain secures data with tamper evident records, protects sensitive health information, and ensures transparent, traceable drug and vaccine distribution to verify product authenticity.

RESULT:

The pharmaceutical regulators worldwide were identifying numerous data integrity deficiencies during inspections.

The major problems included: Poor documentation practices, alternation or manipulation of data, incomplete records, loss of original data.

These issues could lead to: reduced patient safety, substandard pharmaceutical products.

The studyemphasized that the data without integrity has a little value & cannot support product quality decisions.

So there should be a proper recording of data, timely documentation, prevention of unauthorized changes are need to be done. And also concluded that strong documentation practices, protection of original data & implementation of ALCOA principles are essential to maintain data integrity. Recommended following guidelines from USFDA, EMA, Health Canada.

Also discussed on growing concern of data integrity issues in the pharmaceutical & healthcare sectors.Majorconcernsincluded:Regulatory warning letters, loss of business reputation, loss of market value, reduced customer trust.

So, thetop management should activelysupport data integrityinitiatives. The organizations should identify areas vulnerable to data manipulation, high risk process & implement controls accordingly. And companies should establish CAPA systems to investigate data integrity issues & to identify root causes & prevent recurrence, continuous monitoring should conducted to detect & preventpotential data integrity breaches.

Theregulatory agencies were issuing a large number of warning letters due to data integrity deficiencies.

The key problems included: Inaccurate data recording, data manipulation by changing data, failure to comply with FDA regulations. These deficiencies affected drug development, manufacturing operations, product commercialization.

The major problems identified were:

- Growingcomplexityofelectronicdatamanagement.
- Increaseduseofcomputerizedsystems.
- Outsourcingofmanufacturingactivities.
- Continueddata integrityviolationsdespitetheavailabilityofregulatory guidelines.
- Weakorganizationalcultureregardingdataintegrity.
- Poordatabasemanagementsystems.
- Lackofpropertrainingandeducation.
- Weakoversightofcontractmanufacturers.

Although organizations follow guidance from FDA, MHRA, and WHO, data integrity issues continue to occur, indicating that regulations alone are insufficient.

Need to develop an organizational culture where:

Employees under and ethical responsibilities,
Data are recorded honestly,
Transparency is encouraged,

Management promotes integrity.

A strong quality culture reduces intentional and unintentional data integrity breaches.

Regular training programs should be conducted to educate employees about ALCOA Plus principles, regulatory expectations, GDP, electronic data management.

CONCLUSION:

Data integrity is a key element of pharmaceutical quality assurance that ensures data is accurate, complete, consistent, reliable, and secure throughout its lifecycle. The ALCOA, ALCOA+, and ALCOA++ principles provide foundation for maintaining trustworthy data. Regulatory authorities such as the USFDA, EMA, WHO, and MHRA emphasize data integrity due to increasing cases of data manipulation and documentation deficiencies. Common challenges include poor documentation, human errors, in adequate training, outdated systems, and cyber security risks. Effective measures such as data governance, validated computerized systems, audit trails, access controls, and employee training help maintain data integrity. Modern technologies like automation, artificial intelligence, and block chain further strengthen data security and traceability. Therefore, implementing data integrity principles is essential for ensuring product quality, patient safety, regulatory compliance, and public trust in the pharmaceutical industry.

REFERENCES:

1. Divya Gokulakrishnan, Sowmyalakshmi Venkataraman, Ensuring data integrity: bestpractices and strategies in pharmaceutical industry, Intelligent Pharmacy, 2025, Vol.3 No.4. ISSN:2949-866X, Pg No:296-303.
2. https://www.perplexity.ai/search/please-provide-the-pharmaceutiRv6NQS5BTcyWwPJulSZt1gretriveon2-05-2026.
3. Shmmon Ahmad, Ashok Kumar and Dr. Abdul Hafeez, The pharma innovation, Importance of Data Integrity & Its Regulation in PharmaceuticalIndustry,2019,ISSN(E)2277-7695,ISSN(P)2349-8242, PgNo:306-313.
4. Madhanraj S, Anton Smith A, ata integrity in pharmaceuticals, InternationalJournalofDrugRegulatoryAffairs, 2025,ISSN:2321-6794, Page No 26-36.
5. Shmmon Ahmad, Ashok Kumar and Dr. Abdul Hafeez, The pharma innovation, Importance of Data Integrity & Its Regulation in PharmaceuticalIndustry,2019,ISSN(E)2277-7695,ISSN(P)2349-8242, PgNo:306-313.
6. Madhanraj S, Anton Smith A, ata integrity in pharmaceuticals, InternationalJournalofDrugRegulatoryAffairs, 2025,ISSN:2321-6794, Page No 26-36.
7. SanketGade,Dr.PreranaJadhav,Dr.PradyumanaIge,PratikshaBornare, Data integrity compliance, importance, consequences and strategy to overcome data integrity in the pharmaceutical industry, International Journal Of Pharmaceutical Sciences ,2024, Vol 02.
8. Divya Gokulakrishnan, Sowmyalakshmi Venkataraman, Ensuring data integrity:bestpracticesandstrategiesinpharmaceuticalindustry, IntelligentPharmacy,2025,Vol.3No.4.ISSN:2949-866X,PgNo:296-303.
9. P. KirubaRachel, N.VishalGupta, DataIntegrityRegulations&Current Scenario, 2017, ISSN: 0976-044X, Pg No: 16-22.Shmmon Ahmad, Ashok Kumar, Abdul Hafeez, Importance of data integrity & its regulation in pharmaceutical industry, Pharma Innovation Journal ,2018, Pg No: 306-313.
10. Shmmon Ahmad, Ashok Kumar and Dr. Abdul Hafeez, The pharma innovation, Importance of Data Integrity & Its Regulation in PharmaceuticalIndustry,2019,ISSN(E)2277-7695,ISSN(P)2349- 8242, PgNo:306-313.
11. Manoj Kumar Suryakant Bhadrashette, Over view of data integrityissuesinpharmaceuticalindustry,InternationalJournalofPharmaceutical Sciences Review & Research,2018, ISSN 0976 –044X , Article No. 14, Pages: 95-101.
12. Anil K. Rattan, Data Integrity: History, Issues & remediation of Issues, 2018.
13. AdjunctAssociateProfessorSiaChongHock,ChanLaiWah,VernonTay, Vimal Sachdeva, Pharmaceutical DI: Issues, Challenges& Proposed solutions for manufacturers & inspectors, 2020, Vol 9.
14. Vignesh. M, Ganesh G.N.K, Current status, challenges & preventives strategiestoovercomeDIissuesinthepharmaceuticalindustry,2020,Vol 12, ISSN: 0975-7058.
15. Mohammad Zarour, Mamdough Alenezi, Md Tarique Jamal Ansari, Abhishek Kumar Pandey, Massod Ahmad Khan, Alka Agarwal, Rajeev Kumar, Raees Ahmed Khan, Ensuring data integrity of healthcare information in the era of digital health, 2021.
16. Dharnesh. R, Jeyaprakash M.R, An Approach of Data Integrity in Pharmaceutical Industries, 2022.
17. Naseem A. Charoo, Mansoor A. Khan, Ziyaur Rahman, Data Integrity IssuesInPharmaceuticalIndustry: CommonObservations, Challenges & Mitigations Strategies, 2023.
18. M H Ingale, M C Tayade, Y P Patil, Rahul Salunkhe, Data Integrity Violations in the Pharmaceutical Industry and Regulatory

Measures, Internation Journal of Pharmaceutical Quality Assurance ,2023, Pg No: 416-420.

19. KamarajA, Sangamesh Puranik, DI & Meeting the Regulatory Expectations, 2023, Vol 24.
20. Saad Khan, Dania Mohsin Khan, Implementing DI As a Code: Step by Step Guide for Clinical Trials, 2023.SnehalChandrashekhar Jale*, NidheeVinayakTendulkar, SiddhiMaruti Chavan, Sayali Venkat Biradar, Jayshree Kishor Sonawane, Ishwari PrakashNarkar,AayeshaDashrathBargeVaishali iJadhav,DrAshishJain2023, ISSN2582-7421.
21. Snehal Chandrashekhar Jale*, Nidhee Vinayak Tendulkar, Siddhi Maruti Chavan, Sayali Venkat Biradar, Jayshree Kishor Sonawane, Ishwari Prakash Narkar, Aayesha Dashrath Barge, Vaishali Jadhav, Dr Ashish Jain , 2023, ISSN 2582-7421.
22. Sasidhar Duggineni, Data Integrity & risk, 2023.
23. Mrunal M .Sabel, Varun A. Pande, Amol A. Tagallpallewar, Arti G. Swami, Anil. Pawar, Akshay M. Baheti, Maintaining Data Safety & ACCURACY Through Data Integrity (DI): A Comprehensive Review, 2024, Vol 17.
24. Sanket Gade, Prerana Jadav, Pradyumana Ige, Pratiksha Bornare, DI Compliance, Importance, Consequences & Strategy to Overcome DI In ThePharmaceutical Industry, 2024, Vol 2, ISSN: 0975-4725.
25. Pravin Ullagaddi, Safeguarding Data Integrity in Pharmaceutical Manufacturing, Journal of Advices in Medical and Pharmaceutical Sciences, 2024, ISSN: 2394-1111, Vol: 26, Pg No: 64-75.
26. Akshya U. Bhandarkar, Balaji J, Jasvanth R., Dinesh Ragavendra S., Ensuring DI In Pharmaceutical Industry: Benefits, Challenges, Key Considerations & Best Practices, 2024, Vol 2, ISSN: 0975-4725.
27. ArunAyilliathKeezhabadath,LalithaAmarapalli ,EnsuringDataIntegrity inPharmaceuticalQualitySystems:ARisk – BasedApproach, Journalof AI – Powered Medical Innovations.
28. Priti Sanjay Pagar, Mahesh Kailas Wagh, Suraj Sanjay Shelar, Data Integrity Challenges In Pharmaceutical QA And Their Solutions, International Journal of Creative ResearchThoughts, 2025, ISSN: 2320-2882, Vol: 13.
29. Patel Richi & Rajgor Hiral A, DI in PharmaceuticalQualitySystem, 2025, Vol 2.
30. Chanchal Manohar Avchar, Ensuring Data Integrity InThe Pharmaceutical Industry: Challenges & Best Practices, International Journal of Pharmaceutical Science, 2025, Vol 3.
31. Madhanraj S, Anton Smith A, Data integrity in pharmaceuticals, InternationalJournalofDrugRegulatoryAffairs, 2025,ISSN:2321-6794, Page No 26-36.
32. FirozMohammedOzman,Systematicliteraturere viewonthecriticalrole of data integrity in AI-driven enterprises, 2025, ISSN: 2582-8266.
33. GregorMiller,ElmarSpigel,GuidelinesforResea rchDI(GRDI),2025.
34. GaikwadSwapnali,GaiwalSanika,GhodkePrati ksha,GhorpadeIshwari, Gire Nishigandha, Dr. S. D. Mankar, Review on Data IntegrityBased on The Principles Of ALCOA, 2025.
35. Tapamoy Chakraborty, Data Integrity Principles ALCOA+++ Contents, 2025.
36. BiswalShreyaAiay& Chhaya U Shah, Data IntegrityIn Pharmaceutical QualityAssurance:AReview Based onALCOAPrinciples, 2026, Vol8.
37. Buddaraju Vivekananda Raju1, B. Babu, Smita Jain3, JanoriousWinka Jayaprakash4, Jayaprakash Narayanan Jaganathan5, Nagarajan Janaki Sankarachari Krishnana, Evaluating Data Integrity Issues in the Pharmaceutical Industry and Proposing Solutions Through the Pharmaceutical Education Curriculum, 2026, Vol 16.
38. Pravin Ullagaddi, Safeguarding Data Integrity in Pharmaceutical Manufacturing, Journal of Advices in Medical and Pharmaceutical Sciences, 2024 ,ISSN : 2394-1111 ,Vol:26 , Pg No: 64-75.
39. https://pharmadigests.com/objective-of-data-management-and-integrityretriveon3-05-2026.
40. Madhanraj S, Anton Smith A, ata integrity in pharmaceuticals, InternationalJournalofDrugRegulatoryAffairs, 2025,ISSN:2321-6794, Page No 26-36.